Case Reports of Adverse Drug Reactions Induced by Tislelizumab in A Hospital and the Literature Review
10.3870/j.issn.1004-0781.2023.12.022
- VernacularTitle:替雷利珠单抗不良反应病例报告及文献回顾
- Author:
Xiaojian WANG
1
;
Zhe LI
;
Ye XU
;
Chen PAN
;
Xiangli CUI
Author Information
1. 首都医科大学附属北京友谊医院药剂科,北京 100050
- Keywords:
Tislelizumab;
Adverse drug reactions;
Retrospectively analysis
- From:
Herald of Medicine
2023;42(12):1873-1878
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the characteristics of adverse drug reactions(ADRs)induced by tislelizumab and to provide reference for clinic drug safety.Methods The ADR of tislelizumab in Beijing Friendship Hospital Affiliated to Capital Medical Univeristy from July 2021 to December 2022 were retrospectively analyzed.The case reports of ADR induced by tislelizumab from January 2019 to December 2022 in PubMed,ScienceDirect,Embase,Wanfang,VIP databases were searched.Age,sex,original diseases,adverse reaction time,clinical manifestation,treatment measures and clinical outcome were analyzed.Results A total of 30 patients including 8 cases in hospital and 22 cases in literature were collected.Among these patients,male accounted for 83.33%(25/30),and the highest proportion was from patients over 60 years old(21 patients,70.00%).Most ADRs occurred in 1-2 dose cycles of medication,mainly including skin toxicity in 8 patients,digestive disease in 6 patients and kidney injury in 4 patients.After the symptomatic treatment,29 patients improved and 1 patient died.Conclusion During the medication with tislelizumab,ADRs of skin,gastrointestinal tract and renal should be vigilant,and the changes of relevant indicators should be closely monitored.
